Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study – Alzamend Neuro (NASDAQ:ALZN)
[ad_1] Alzamend Neuro Inc ALZN submitted an investigational new drug application to the FDA for its immunotherapy candidate, ALZN002. The product candidate is designed to treat mild to moderate dementia of…